Synergistic inhibition of angiogenesis by artesunate and captopril in vitro and in vivo

Publication type:
Journal article
Metadata:
Autoren
  • Benjamin Krusche
  • Joachim Arend
  • Thomas Efferth
Sammlungen
  • metadata
ISSN
1741-4288
Zeitschrift
Evidence-based complementary and alternative medicine
Schlüsselwörter
  • 570 Biowissenschaften
  • 570 Life sciences
Sprache
eng
Paginierung
Art. 454783
Datum der Veröffentlichung
2013
Herausgeber
Hindawi
Herausgeber URL
http://dx.doi.org/10.1155/2013/454783
Datum der Datenerfassung
2020
Datum, an dem der Datensatz öffentlich gemacht wurde
2020
Zugang
Public
Titel
Synergistic inhibition of angiogenesis by artesunate and captopril in vitro and in vivo
Ausgabe der Zeitschrift
2013

Data source: METADATA.UB

Other metadata sources:
Autoren
  • Benjamin Krusche
  • Joachim Arend
  • Thomas Efferth
Autoren-URL
https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=fis-test-1&SrcAuth=WosAPI&KeyUT=WOS:000325882900001&DestLinkType=FullRecord&DestApp=WOS_CPL
DOI
10.1155/2013/454783
eISSN
1741-4288
Externe Identifier
  • Clarivate Analytics Document Solution ID: 237PN
  • PubMed Identifier: 24223058
ISSN
1741-427X
Zeitschrift
EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
Artikelnummer
ARTN 454783
Datum der Veröffentlichung
2013
Status
Published
Titel
Synergistic Inhibition of Angiogenesis by Artesunate and Captopril <i>In Vitro</i> and <i>In Vivo</i>
Sub types
  • Article
Ausgabe der Zeitschrift
2013

Data source: Web of Science (Lite)

Abstract
<jats:p>Inhibition of angiogenesis represents one major strategy of cancer chemotherapy. In the present investigation, we investigated the synergism of artesunate and captopril to inhibit angiogenesis. Artesunate is an antimalarial derivative of artemisinin from the Chinese medicinal plant,<jats:italic>Artemisia annua</jats:italic>L., which also reveals profound anticancer activity<jats:italic>in vitro</jats:italic>and<jats:italic>in vivo</jats:italic>. Captopril is an angiotensin I-converting (ACE) inhibitor, which is well established in Western academic medicine. Both compounds inhibited migration of human umbilical vein endothelial cells (HUVECs)<jats:italic>in vitro</jats:italic>. The combination of both drugs resulted in synergistically inhibited migration. Whereas artesunate inhibited HUVEC growth in the XTT assay, captopril did not, indicating independent modes of action. We established a chorioallantoic membrane (CAM) assay of quail embryos (<jats:italic>Coturnix coturnix</jats:italic>L.) and a computer-based evaluation routine for quantitative studies on vascularization processes<jats:italic>in vivo</jats:italic>. Artesunate and captopril inhibited blood vessel formation and growth. For the first time, we demonstrated that both drugs revealed synergistic effects when combined. These results may also have clinical impact, since cardiovascular diseases and cancer frequently occur together in older cancer patients. Therefore, comorbid patients may take advantage, if they take captopril to treat cardiovascular symptoms and artesunate to treat cancer.</jats:p>
Autoren
  • Benjamin Krusche
  • Joachim Arend
  • Thomas Efferth
DOI
10.1155/2013/454783
eISSN
1741-4288
ISSN
1741-427X
Zeitschrift
Evidence-Based Complementary and Alternative Medicine
Sprache
en
Paginierung
1 - 10
Datum der Veröffentlichung
2013
Status
Published
Herausgeber
Hindawi Limited
Herausgeber URL
http://dx.doi.org/10.1155/2013/454783
Datum der Datenerfassung
2022
Titel
Synergistic Inhibition of Angiogenesis by Artesunate and Captopril<i>In Vitro</i>and<i>In Vivo</i>
Ausgabe der Zeitschrift
2013

Data source: Crossref

Abstract
Inhibition of angiogenesis represents one major strategy of cancer chemotherapy. In the present investigation, we investigated the synergism of artesunate and captopril to inhibit angiogenesis. Artesunate is an antimalarial derivative of artemisinin from the Chinese medicinal plant, Artemisia annua L., which also reveals profound anticancer activity in vitro and in vivo. Captopril is an angiotensin I-converting (ACE) inhibitor, which is well established in Western academic medicine. Both compounds inhibited migration of human umbilical vein endothelial cells (HUVECs) in vitro. The combination of both drugs resulted in synergistically inhibited migration. Whereas artesunate inhibited HUVEC growth in the XTT assay, captopril did not, indicating independent modes of action. We established a chorioallantoic membrane (CAM) assay of quail embryos (Coturnix coturnix L.) and a computer-based evaluation routine for quantitative studies on vascularization processes in vivo. Artesunate and captopril inhibited blood vessel formation and growth. For the first time, we demonstrated that both drugs revealed synergistic effects when combined. These results may also have clinical impact, since cardiovascular diseases and cancer frequently occur together in older cancer patients. Therefore, comorbid patients may take advantage, if they take captopril to treat cardiovascular symptoms and artesunate to treat cancer.
Addresses
  • Department of Pharmaceutical Biology, Institute of Pharmacy and Biochemistry, Johannes Gutenberg University, Staudinger Weg 5, 55128 Mainz, Germany.
Autoren
DOI
10.1155/2013/454783
eISSN
1741-4288
Externe Identifier
  • PubMed Identifier: 24223058
  • PubMed Central ID: PMC3816047
Open access
true
ISSN
1741-427X
Zeitschrift
Evidence-based complementary and alternative medicine : eCAM
Sprache
eng
Medium
Print-Electronic
Online publication date
2013
Open access status
Open Access
Paginierung
454783
Datum der Veröffentlichung
2013
Status
Published
Publisher licence
CC BY
Datum der Datenerfassung
2013
Titel
Synergistic inhibition of angiogenesis by artesunate and captopril in vitro and in vivo.
Sub types
  • research-article
  • Journal Article
Ausgabe der Zeitschrift
2013

Files

https://downloads.hindawi.com/journals/ecam/2013/454783.pdf https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24223058/pdf/?tool=EBI https://europepmc.org/articles/PMC3816047?pdf=render

Data source: Europe PubMed Central

Abstract
Inhibition of angiogenesis represents one major strategy of cancer chemotherapy. In the present investigation, we investigated the synergism of artesunate and captopril to inhibit angiogenesis. Artesunate is an antimalarial derivative of artemisinin from the Chinese medicinal plant, Artemisia annua L., which also reveals profound anticancer activity in vitro and in vivo. Captopril is an angiotensin I-converting (ACE) inhibitor, which is well established in Western academic medicine. Both compounds inhibited migration of human umbilical vein endothelial cells (HUVECs) in vitro. The combination of both drugs resulted in synergistically inhibited migration. Whereas artesunate inhibited HUVEC growth in the XTT assay, captopril did not, indicating independent modes of action. We established a chorioallantoic membrane (CAM) assay of quail embryos (Coturnix coturnix L.) and a computer-based evaluation routine for quantitative studies on vascularization processes in vivo. Artesunate and captopril inhibited blood vessel formation and growth. For the first time, we demonstrated that both drugs revealed synergistic effects when combined. These results may also have clinical impact, since cardiovascular diseases and cancer frequently occur together in older cancer patients. Therefore, comorbid patients may take advantage, if they take captopril to treat cardiovascular symptoms and artesunate to treat cancer.
Date of acceptance
2013
Autoren
  • Benjamin Krusche
  • Joachim Arend
  • Thomas Efferth
Autoren-URL
https://www.ncbi.nlm.nih.gov/pubmed/24223058
DOI
10.1155/2013/454783
Externe Identifier
  • PubMed Central ID: PMC3816047
ISSN
1741-427X
Zeitschrift
Evid Based Complement Alternat Med
Sprache
eng
Country
United States
Paginierung
454783
Datum der Veröffentlichung
2013
Status
Published
Datum, an dem der Datensatz öffentlich gemacht wurde
2013
Titel
Synergistic inhibition of angiogenesis by artesunate and captopril in vitro and in vivo.
Sub types
  • Journal Article
Ausgabe der Zeitschrift
2013

Data source: PubMed

Author's licence
CC-BY
Autoren
  • Benjamin Krusche
  • Joachim Arend
  • Thomas Efferth
Hosting institution
Universitätsbibliothek Mainz
Sammlungen
  • DFG-OA-Publizieren (2012 - 2017)
Resource version
Published version
DOI
10.1155/2013/454783
Funding acknowledgements
  • DFG, Open Access-Publizieren Universität Mainz / Universitätsmedizin
File(s) embargoed
false
Open access
true
ISSN
1741-4288
Zeitschrift
Evidence-based complementary and alternative medicine
Schlüsselwörter
  • 570 Biowissenschaften
  • 570 Life sciences
Sprache
eng
Open access status
Open Access
Paginierung
Art. 454783
Datum der Veröffentlichung
2013
Public URL
https://openscience.ub.uni-mainz.de/handle/20.500.12030/7855
Herausgeber
Hindawi
Herausgeber URL
http://dx.doi.org/10.1155/2013/454783
Datum der Datenerfassung
2022
Datum, an dem der Datensatz öffentlich gemacht wurde
2022
Zugang
Public
Titel
Synergistic inhibition of angiogenesis by artesunate and captopril in vitro and in vivo
Ausgabe der Zeitschrift
2013

Files

synergistic_inhibition_of_ang-20221005103458805.pdf

Data source: OPENSCIENCE.UB

Beziehungen:
Property of

Tools